Product Description
Glutamine is the most abundant and versatile amino acid in the body. Glutamine is the most abundant and versatile amino acid in the body, and is of fundamental importance to intermediary metabolism, interorgan nitrogen exchange via ammonia (NH3) transport between tissues, and pH homeostasis. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266414/)
Mechanisms of Action: GLS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: Orphan Drug - *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Czech | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Korea | Latvia | Lebanon | Lithuania | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Anemia, Sickle Cell
Known Adverse Events: Abdominal Pain | Back Pain | Chest Pain | Headache | Pain Unspecified | Constipation
Company: Emmaus Medical
Company Location: TORRANCE CA 90503
Company CEO: Yutaka Niihara
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Adenocarcinoma|Colonic Diseases|Diverticulosis, Colonic|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GlutaPanc | P1 |
Active, not recruiting |
Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma |
2023-07-06 |
|
| EM-DsD-002 | P1 |
Completed |
Diverticulosis, Colonic|Colonic Diseases |
2022-12-30 |
21% |